Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
– GATHER2 Enrollment and Retention Continue to Exceed Expectations; Completion of Enrollment Expected Late July